In Q4FY26, Granules India Limited reported revenue from operations of Rs 14,706 million, marking a 23% year-on-year growth and a 6% sequential increase.

EBITDA rose sharply by 40% YoY to Rs 3,521 million, with margins improving to 24% from 21% in the corresponding quarter last year. Profit after tax (PAT) stood at Rs 2,016 million, up 33% YoY, translating to a PAT margin of 14%.

For the full year FY26, revenue grew 20% YoY to Rs 53,656 million, while EBITDA increased 25% to Rs 11,851 million, expanding margins to 22%. PAT for the year reached Rs 5,950 million, up 19% YoY, maintaining a steady net profit margin of 11%.

Geographically, North America remained the largest contributor, accounting for 72% of Q4FY26 revenues, though down from 79% in Q4FY25, while Europe saw a significant rise to 17% from 8%, indicating diversification of revenue streams.

From a segment perspective, finished dosages (FD) contributed 73% of revenues in Q4FY26, followed by APIs at 13%, PFIs at 9%, and Peptide/CDMO at 5%, highlighting the company’s expanding footprint in complex and high-value segments.

Operational efficiency also improved, with return on capital employed (ROCE) rising to 17.6% in FY26 from 16.6% in FY25. The company strengthened its balance sheet, reducing net debt year-on-year by Rs 3,040 million to Rs 4,021 million, improving the net debt-to-EBITDA ratio to 0.34x.

Commenting on the performance, Chairman and Managing Director Dr. Krishna Prasad Chigurupati said the company’s strong Q4 results were driven by portfolio expansion, disciplined execution, and progress across regulatory, compliance, and sustainability initiatives. He emphasized continued momentum in complex generics and the peptides CDMO platform as key growth drivers.